252 related articles for article (PubMed ID: 29665040)
1. Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma.
Klimko PG; Sharif NA
Br J Pharmacol; 2019 Apr; 176(8):1051-1058. PubMed ID: 29665040
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.
Impagnatiello F; Bastia E; Almirante N; Brambilla S; Duquesroix B; Kothe AC; Bergamini MVW
Br J Pharmacol; 2019 Apr; 176(8):1079-1089. PubMed ID: 29669171
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
Lin L; Zhao YJ; Chew PT; Sng CC; Wong HT; Yip LW; Wu TS; Bautista D; Teng M; Khoo AL; Lim BP
Ann Pharmacother; 2014 Dec; 48(12):1585-93. PubMed ID: 25184309
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
Ota T; Murata H; Sugimoto E; Aihara M; Araie M
Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2006-11. PubMed ID: 15914616
[TBL] [Abstract][Full Text] [Related]
5. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice.
Ota T; Aihara M; Narumiya S; Araie M
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4159-63. PubMed ID: 16249494
[TBL] [Abstract][Full Text] [Related]
6. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues.
Sharif NA; Kelly CR; Crider JY
Invest Ophthalmol Vis Sci; 2003 Feb; 44(2):715-21. PubMed ID: 12556403
[TBL] [Abstract][Full Text] [Related]
7. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor.
Sharif NA; Kelly CR; Crider JY
J Ocul Pharmacol Ther; 2002 Aug; 18(4):313-24. PubMed ID: 12222762
[TBL] [Abstract][Full Text] [Related]
8. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma.
Sharif NA; Odani-Kawabata N; Lu F; Pinchuk L
Exp Eye Res; 2023 Apr; 229():109415. PubMed ID: 36803996
[TBL] [Abstract][Full Text] [Related]
9. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells.
Sharif NA; Kelly CR; Crider JY; Williams GW; Xu SX
J Ocul Pharmacol Ther; 2003 Dec; 19(6):501-15. PubMed ID: 14733708
[TBL] [Abstract][Full Text] [Related]
10. Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes.
Gagliuso DJ; Wang RF; Mittag TW; Podos SM
Arch Ophthalmol; 2004 Sep; 122(9):1342-7. PubMed ID: 15364714
[TBL] [Abstract][Full Text] [Related]
11. Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy.
Miki T; Naito T; Fujiwara M; Araki R; Kiyoi R; Shiode Y; Fujiwara A; Morizane Y; Shiraga F
PLoS One; 2017; 12(7):e0181550. PubMed ID: 28727804
[TBL] [Abstract][Full Text] [Related]
12. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
Li N; Chen XM; Zhou Y; Wei ML; Yao X
Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy.
Denis P; Lafuma A; Khoshnood B; Mimaud V; Berdeaux G
Curr Med Res Opin; 2007 Mar; 23(3):601-8. PubMed ID: 17355741
[TBL] [Abstract][Full Text] [Related]
14. Microvascular effects of selective prostaglandin analogues in the eye with special reference to latanoprost and glaucoma treatment.
Stjernschantz J; Selén G; Astin M; Resul B
Prog Retin Eye Res; 2000 Jul; 19(4):459-96. PubMed ID: 10785618
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility.
Sharif NA; Klimko PG
Br J Pharmacol; 2019 Apr; 176(8):1059-1078. PubMed ID: 29679483
[TBL] [Abstract][Full Text] [Related]
16. Travoprost--a new prostaglandin analogue for the treatment of glaucoma.
Whitson JT
Expert Opin Pharmacother; 2002 Jul; 3(7):965-77. PubMed ID: 12083996
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.
Dubiner HB; Sircy MD; Landry T; Bergamini MV; Silver LH; Darell Turner F; Robertson S; Andrew RM; Weiner A; Przydryga J
Clin Ther; 2004 Jan; 26(1):84-91. PubMed ID: 14996520
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018).
Angeli A; Supuran CT
Expert Opin Ther Pat; 2019 Oct; 29(10):793-803. PubMed ID: 31462124
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
Noecker RJ; Walt JG
Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
[TBL] [Abstract][Full Text] [Related]
20. Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma.
Brown GC; Brown MM
J Ocul Pharmacol Ther; 2019 Apr; 35(3):145-160. PubMed ID: 30920338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
